SCHEMBL16495479

SCHEMBL16495479

Cc1cccc(-c2ccc(C(=O)NCc3ccccc3)cn2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 8/20 0.77
L3MBTL1 Q9Y468 1/20 0.56
BAZ2B Q9UIF8 1/20 0.53
EPHX2 P34913 1/20 0.52
NR1H4 Q96RI1 1/20 0.52
CFD P00746 1/20 0.51
ALOX15 P16050 1/20 0.51
VNN1 O95497 1/20 0.51
PSMD14 O00487 1/20 0.51
COPS5 Q92905 1/20 0.51
JAK2 O60674 1/20 0.51
MAP4K4 O95819 1/20 0.51
CHEK2 O96017 1/20 0.51
PRKCG P05129 1/20 0.51
CDK1 P06493 1/20 0.51
FES P07332 1/20 0.51
RET P07949 1/20 0.51
ROS1 P08922 1/20 0.51
FER P16591 1/20 0.51
FLT1 P17948 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495662 0.93 HPGDS (0.65) HPGDSEPHX2NR1H4LMNA
SCHEMBL16496197 0.90 HPGDS (0.61) HPGDSL3MBTL1EPHX2
SCHEMBL16495588 0.90 HPGDS (0.61) HPGDSL3MBTL1COPS5LMNA
SCHEMBL16495648 0.90 HPGDS (0.61) HPGDSEPHX2NR1H4
SCHEMBL16495515 0.89 HPGDS (0.60) HPGDSROCK1
SCHEMBL16495972 0.89 HPGDS (0.60) HPGDSEPHX2NR1H4COPS5ROCK1
SCHEMBL16496053 0.88 HPGDS (0.59) HPGDSEPHX2NR1H4PSMD14COPS5
SCHEMBL16495657 0.87 HPGDS (1.00) HPGDSL3MBTL1BAZ2BEPHX2NR1H4
SCHEMBL16495585 0.87 HPGDS (0.58) HPGDSEPHX2PSMD14
SCHEMBL16495389 0.87 HPGDS (0.58) HPGDSEPHX2NR1H4MAPK9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306597-A1 Nicotinamide Derivatives CRAWFORTH JAMES MICHAEL (GB) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306597-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 HPGDS 1073/4885L3MBTL1 4532/4885BAZ2B 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.